Our Science

Think Outside the Brain

From overturning the old dogma to a new therapeutic approach for neurodegeneration

01 | Scientific foundation

Prof. Michal Schwartz challenged the old dogma

The brain was long viewed as largely immune-isolated. Her research helped establish a fundamentally different paradigm: the brain depends on regulated support from the peripheral immune system for maintenance, resilience and repair.

From the brain immune privilege to privileged immunity of the brain

Old dogma

The brain is completely isolated from the immune system

  1. Lymphatic-like vessels in meninges (ignored)
    1787
  2. The brain is physically isolated
    Blood-Brain-Barrier
    1885
  3. The brain is functionally isolated
    Immune privilege
    1948

Contemporary understanding

The brain is NOT isolated from the immune system

  1. Peripheral immune cells (protective autoimmunity; T cell and monocyte-derived macrophages) support CNS repair
    1998/1999
  2. Brain functional plasticity is tightly dependent on the immune system
    2004/2006
  3. Meningeal and blood-cerebrospinal barriers serve as immunological niches and gateways
    2013
  4. The brain is equipped with structural and functional lymphatic system
    2015

This discovery is the scientific foundation of Immunobrain. Rather than treating peripheral immunity as a threat to be excluded from the CNS, our approach is built on restoring a physiological brain-immune dialogue that becomes impaired with aging and neurodegenerative disease.

Sources: Schwartz, Neuron, 2026 (source of scheme); Castellani, Croese, Peralta Ramos & Schwartz, Science, 2023; Schwartz et al., Neuron, 2022.

02 | Brain-immune ecosystem

The brain relies on peripheral immunity

Peripheral immune cells support brain maintenance remotely and can be recruited through specialized CNS interfaces when repair is needed.

The key implication is that brain repair is not performed by resident cells alone. CNS borders, meninges and the choroid plexus provide regulated routes for immune communication and selective recruitment of protective peripheral cells.

Sources: Croese, Castellani & Schwartz, Nature Immunology, 2021; Castellani et al., Science, 2023.

03 | What changes with aging

Aging disrupts both the brain and the periphery

Neurodegeneration develops in the setting of chronic brain inflammation and declining peripheral immune competence.

With aging, microglia can acquire dysfunctional and senescent states while peripheral immunity becomes less capable of mounting an effective repair response. The result is a failure to resolve inflammation, increasing vulnerability of synapses and neurons.

Sources: Baruch, Deczkowska et al., Science, 2014; Deczkowska et al., Nature Communications, 2017.

Alzheimer's disease progression is driven by neuroinflammation and systemic immune aging

Peripheral immune aging
Ageing
Neuroinflammation / microglial dysfunction
Neuronal / synaptic damage
Cognitive decline
Amyloid accumulation & tau pathology

Immunobrain

Rejuvenation of the immune system renews brain-immune dialogue, facilitates the homing of immune-repairing cells that clear senescent microglia, and resolves inflammation. It can rescue dysfunctional neurons, providing neuroprotection.

04 | Why peripheral macrophages matter

Resident microglia and recruited macrophages are not redundant

Macrophages are essential for brain repair: a central insight from the Schwartz laboratory is that resident microglia alone may be insufficient for repair under pathological conditions.

Peripheral macrophages are required for CNS repair
Recruited macrophages show distinct anti-inflammatory repair functions

Monocyte-derived macrophages originate outside the brain and can be recruited when repair is required. Once recruited, they can display scavenging and inflammation-resolving properties that are distinct from resident microglia. This provides the biological rationale for therapeutically mobilizing peripheral immunity rather than simply suppressing inflammation inside the brain.

Sources: Shechter et al., PLoS Medicine, 2009.

05 | Why anti-PD-L1

Use an immune checkpoint as a temporary switch

The PD-1/PD-L1 pathway restrains T-cell activity. Transient checkpoint blockade can briefly release that brake and initiate a coordinated peripheral repair response.

PD-1/PD-L1 blockade transiently activates peripheral T cells
A short immune pulse can precede delayed, lasting cognitive benefit

The goal is not chronic immune activation. Preclinical work showed that a brief checkpoint-blocking signal can trigger downstream events that outlast antibody exposure. In this model, anti-PD-L1 acts as an instructor: it initiates the immune cascade, while recruited cells execute the repair response in the CNS.

Sources: Baruch et al., Nature Medicine, 2016.

06 | Mechanistic proof

The anti-PD-L1 beneficial effect depends on monocyte-derived macrophage recruitment

Checkpoint blockade promotes brain homing of monocytes and Tregs, and blocking the monocyte recruitment pathway removes the beneficial effect.

Anti-PD-L1 promotes monocyte and Treg homing
Blocking CCR2 abrogates effects on behavior, pathology, neuronal survival and inflammation

This is a critical mechanistic link: the response is not explained simply by peripheral T-cell activation. CCR2-dependent monocyte recruitment is required for the downstream CNS effects, identifying monocyte-derived macrophage recruitment as a key mediator of the beneficial effect.

Sources: Ben-Yehuda et al., Molecular Neurodegeneration, 2021; Raposo et al., Journal of Neuroscience, 2014.

07 | TREM2 independence

Anti-PD-L1 beneficial effect bypasses TREM2 polymorphism through monocyte-derived macrophage recruitment

A major implication of the macrophage-driven mechanism is that benefit is not dependent on intact TREM2 signaling in resident microglia.

In 5xFAD models, anti-PD-L1 improved behavioral outcomes in both Trem2+/+ and Trem2-/- backgrounds. Together with the CCR2 experiments, this supports a model in which recruited monocyte-derived macrophages can provide a complementary repair pathway when resident microglial function is compromised.

Sources: Dvir-Szternfeld, Castellani, Arad et al. & Schwartz, Nature Aging, 2022.

08 | What happens inside the brain

Recruited macrophages facilitate the removal of senescent microglia and reduce inflammation

The downstream response includes clearance of senescent microglia, reduced inflammatory signaling and preservation of synaptic function.

Systemic anti-PD-L1 reduces senescent microglia in a monocyte-dependent manner
Reduced astrogliosis/inflammatory cytokines with synaptic rescue

These findings connect the peripheral immune trigger to the CNS outcome: recruited immune cells alter the microglial landscape and help resolve chronic neuroinflammation, followed by downstream effects on synaptic and neuronal integrity.

Sources: Rachmian et al. & Schwartz, Nature Neuroscience, 2024; Rosenzweig et al. & Schwartz, Nature Communications, 2019.

09 | Translation into IBC-Ab002

IBC-Ab002 is engineered based on the mechanism of action in animal models of dementia

A fully human anti-PD-L1 designed for transient, controlled peripheral immune activation rather than continuous checkpoint inhibition.

IBC-Ab002 combines high-affinity PD-L1 binding with Fc modification eliminating ADCC/CDC and a short half-life designed to limit prolonged systemic exposure. The therapeutic concept is intermittent dosing: a short peripheral immune signal that initiates a longer-lived repair response.

References

  1. Baruch, Deczkowska et al., Science, 2014.
  2. Baruch et al., Nature Medicine, 2016.
  3. Ben-Yehuda et al., Molecular Neurodegeneration, 2021.
  4. Castellani, Croese, Peralta Ramos & Schwartz, Science, 2023.
  5. Croese, Castellani & Schwartz, Nature Immunology, 2021.
  6. Deczkowska et al., Nature Communications, 2017.
  7. Dvir-Szternfeld, Castellani, Arad et al. & Schwartz, Nature Aging, 2022.
  8. Rachmian et al. & Schwartz, Nature Neuroscience, 2024.
  9. Raposo et al., Journal of Neuroscience, 2014.
  10. Rosenzweig et al. & Schwartz, Nature Communications, 2019.
  11. Schwartz, Neuron, 2026.
  12. Schwartz et al., Neuron, 2022.
  13. Shechter et al., PLoS Medicine, 2009.